Vatalanib (PTK787) 2HClTyrosine kinase receptor inhibitor CAS# 212141-51-0 |
- Lapatinib Ditosylate
Catalog No.:BCC2083
CAS No.:388082-78-8
- Pazopanib (GW-786034)
Catalog No.:BCC1286
CAS No.:444731-52-6
- AST 487
Catalog No.:BCC1373
CAS No.:630124-46-8
- Nintedanib (BIBF 1120)
Catalog No.:BCC3661
CAS No.:656247-17-5
- Regorafenib
Catalog No.:BCC3646
CAS No.:755037-03-7
- RAF265
Catalog No.:BCC3677
CAS No.:927880-90-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 212141-51-0 | SDF | Download SDF |
PubChem ID | 22386467 | Appearance | Powder |
Formula | C20H17Cl3N4 | M.Wt | 419.73 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | PTK787 dihydrochloride; PTK/ZK dihydrochloride; CGP-79787D dihydrochloride; CGP-79787 dihydrochloride; ZK-222584 dihydrochloride | ||
Solubility | DMSO : ≥ 125 mg/mL (297.81 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;dihydrochloride | ||
SMILES | C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4.Cl.Cl | ||
Standard InChIKey | AZUQEHCMDUSRLH-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C20H15ClN4.2ClH/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14;;/h1-12H,13H2,(H,23,25);2*1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.In Vitro:Vatalanib also inhibits Flk, c-Kit and PDGFRβ with IC50 of 270 nM, 730 nM and 580 nM, respectively. Vatalanib shows the anti-proliferation effect by inhibiting thymidine incorporation induced by VEGF in HUVECs with and IC50 of 7.1 nM, and dose-dependently suppresses VEGF-induced survival and migration of endothelial cells in the same dose range without cytotoxic or antiproliferative effect on cells that do not express VEGF receptors[1]. A recent study shows that Vatalanib significantly inhibits the growth of hepatocellular carcinoma cells and enhances the IFN/5-FU induced apoptosis by increasing proteins levels of Bax and reduced Bcl-xL and Bcl-2[2].In Vivo:Vatalanib induces dose-dependent inhibition of the angiogenic response to VEGF and PDGF in both a growth factor implant model and a tumor cell-driven angiogenesis model after once-daily oral dosing (25-100 mg/kg). In the same dose range, Vatalanib also inhibits the growth and metastasesof several human carcinomas in nude mice without significant effect on circulating blood cells or bone marrow leukocytes[1]. References: |
Vatalanib (PTK787) 2HCl Dilution Calculator
Vatalanib (PTK787) 2HCl Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3825 mL | 11.9124 mL | 23.8248 mL | 47.6497 mL | 59.5621 mL |
5 mM | 0.4765 mL | 2.3825 mL | 4.765 mL | 9.5299 mL | 11.9124 mL |
10 mM | 0.2382 mL | 1.1912 mL | 2.3825 mL | 4.765 mL | 5.9562 mL |
50 mM | 0.0476 mL | 0.2382 mL | 0.4765 mL | 0.953 mL | 1.1912 mL |
100 mM | 0.0238 mL | 0.1191 mL | 0.2382 mL | 0.4765 mL | 0.5956 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Vatalanib, also known as PTK787, is a potent vascular endothelial growth factor (VEGF) receptor tyrosine kinases inhibitor that inhibits VEGF receptor/KDR, VEGF receptor/Flt-1 and VEGF receptor/Flk with the half maximal inhibition concentration IC50 values of 0.037 μM, 0.077 μM and 0.27 μM respectively [1].
Vatalanib also inhibits other tyrosine kinases belonging to the same family of tyrosine kinase receptors as the VEGF receptors, including the platelet-derived growth factor receptor β tyrosine kinase (PDGFR-β), c-Kit and c-Fms, to a lesser degree with IC50 values of 0.58 μM, 0.73 μM and 1.4 μM respectively [1].
Vatalanib has been found to be potentially therapeutic for the treatment of angiogenesis-related diseases including solid tumors [1].
References:
[1] Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000 Apr 15;60(8):2178-89.
- 1,3,7-Trihydroxy-2-methoxyxanthone
Catalog No.:BCN7549
CAS No.:211948-69-5
- BIBR-1048
Catalog No.:BCC3738
CAS No.:211915-06-9
- BIBR 953 (Dabigatran, Pradaxa)
Catalog No.:BCC2139
CAS No.:211914-51-1
- Gliclazide
Catalog No.:BCC5002
CAS No.:21187-98-4
- Flumorph
Catalog No.:BCC5467
CAS No.:211867-47-9
- Nudicaucin A
Catalog No.:BCN7842
CAS No.:211815-97-3
- 2',4',5'-Trimethoxy-2'',2''-dimethylpyrano[5'',6'':6,7]isoflavone
Catalog No.:BCN1496
CAS No.:211799-56-3
- Picroside IV
Catalog No.:BCN6533
CAS No.:211567-04-3
- Nudicaucin B
Catalog No.:BCN7843
CAS No.:211557-36-7
- WHI-P180
Catalog No.:BCC3928
CAS No.:211555-08-7
- WHI-P97
Catalog No.:BCC2056
CAS No.:211555-05-4
- WHI-P154
Catalog No.:BCC2202
CAS No.:211555-04-3
- Vatalanib
Catalog No.:BCC2085
CAS No.:212141-54-3
- Apparicine
Catalog No.:BCN4008
CAS No.:2122-36-3
- 5,7-Dihydroxy-3-(4-hydroxy-3,5-dimethoxybenzyl)-6,8-dimethylchroman-4-one
Catalog No.:BCN6631
CAS No.:212201-12-2
- Ipfencarbazone
Catalog No.:BCC5465
CAS No.:212201-70-2
- Ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate
Catalog No.:BCC8971
CAS No.:212322-56-0
- TC 2559 difumarate
Catalog No.:BCC7469
CAS No.:212332-35-9
- HS 024
Catalog No.:BCC5820
CAS No.:212370-59-7
- Oxaprozin
Catalog No.:BCC9109
CAS No.:21256-18-8
- Ebracteolatanolide A
Catalog No.:BCN3773
CAS No.:212563-72-9
- Nocistatin (human)
Catalog No.:BCC5732
CAS No.:212609-11-5
- PD 198306
Catalog No.:BCC7428
CAS No.:212631-61-3
- PD184352 (CI-1040)
Catalog No.:BCC1112
CAS No.:212631-79-3